AstraZeneca to buy U.S. rights for gout drug for up to $265 mln

April 26 (Reuters) - British drugmaker AstraZeneca Plc said it would buy the U.S. marketing rights for Ironwood Pharmaceuticals Inc's newly-approved gout drug for up to $265 million.